1. Home
  2. GRCE

as 03-31-2025 2:26pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

NYSE

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Founded: 2002 Country:
United States
United States
Employees: N/A City: PRINCETON
Market Cap: 32.1M IPO Year: N/A
Target Price: $12.00 AVG Volume (30 days): 32.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.16 EPS Growth: N/A
52 Week Low/High: $2.07 - $4.97 Next Earning Date: 05-15-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: